Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) was the recipient of a significant increase in short interest in August. As of August 31st, there was short interest totalling 2,798,560 shares, an increase of 26.7% from the August 15th total of 2,208,469 shares. Based on an average daily trading volume, of 714,912 shares, the short-interest ratio is presently 3.9 days. Approximately 5.6% of the shares of the stock are short sold.

A number of equities analysts have commented on the stock. Chardan Capital restated a “buy” rating and issued a $10.00 price target on shares of Aralez Pharmaceuticals in a research report on Friday, September 16th. Guggenheim reaffirmed a “buy” rating and issued a $12.00 target price on shares of Aralez Pharmaceuticals in a research note on Thursday, September 15th.

In other Aralez Pharmaceuticals news, Director Robert Paul Harris sold 150,000 shares of the business’s stock in a transaction dated Thursday, September 15th. The shares were sold at an average price of $5.82, for a total value of $873,000.00. Following the transaction, the director now directly owns 669,094 shares in the company, valued at $3,894,127.08. The transaction was disclosed in a document filed with the SEC, which is available through this link. 6.77% of the stock is currently owned by company insiders.

Hedge funds have recently bought and sold shares of the company. California Public Employees Retirement System raised its position in Aralez Pharmaceuticals by 10.0% in the second quarter. California Public Employees Retirement System now owns 105,867 shares of the company’s stock worth $349,000 after buying an additional 9,667 shares in the last quarter. Alps Advisors Inc. raised its position in Aralez Pharmaceuticals by 24.9% in the second quarter. Alps Advisors Inc. now owns 89,850 shares of the company’s stock worth $297,000 after buying an additional 17,920 shares in the last quarter. Janus Capital Management LLC raised its position in Aralez Pharmaceuticals by 1.3% in the second quarter. Janus Capital Management LLC now owns 1,603,757 shares of the company’s stock worth $5,292,000 after buying an additional 20,623 shares in the last quarter. FNY Managed Accounts LLC raised its position in Aralez Pharmaceuticals by 73.3% in the second quarter. FNY Managed Accounts LLC now owns 52,000 shares of the company’s stock worth $172,000 after buying an additional 22,000 shares in the last quarter. Finally, Bank of Montreal Can acquired a new position in Aralez Pharmaceuticals during the second quarter worth approximately $100,000. Institutional investors own 49.63% of the company’s stock.

Aralez Pharmaceuticals (NASDAQ:ARLZ) opened at 5.105 on Friday. The company’s market capitalization is $333.06 million. The firm has a 50 day moving average of $5.13 and a 200-day moving average of $4.18. Aralez Pharmaceuticals has a 52 week low of $3.10 and a 52 week high of $8.59.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last posted its earnings results on Tuesday, August 9th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.08. The company had revenue of $12.60 million for the quarter, compared to analyst estimates of $9.70 million. Aralez Pharmaceuticals had a negative return on equity of 73.21% and a negative net margin of 224.35%. The business’s revenue was up 142.3% on a year-over-year basis. On average, analysts forecast that Aralez Pharmaceuticals will post ($1.05) earnings per share for the current year.

Aralez Pharmaceuticals Company Profile

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

5 Day Chart for NASDAQ:ARLZ

Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.